Drug news
EC approves Inlyta (Pfizer) for Real Cell Carcinoma
The European Commission (EC) has granted marketing authorization for Inlyta (axitinib) from Pfizer for the treatment of adult patients with advanced Renal Cell Carcinoma a type of kidney cancer, after failure of prior treatment with sunitinib or a cytokine. The Inlyta data demonstrates a statistically significant improvement in progression free survival compared with sorafenib, and supports the continued role for VEGFR-targeted therapy, following the first-line standard of care,Sutent.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins